Clinical Evidence
Explore the peer-reviewed evidence behind our current care, along with clearly labeled educational research on emerging therapies.
Evidence behind current care
American Journal of Psychiatry
2019
FDA-approvedClinical trials support esketamine for adults whose depression has not improved with previous treatments; since January 2025 it is also FDA-approved as a standalone treatment.
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression
Journal of Psychiatric Research
2022
Meta-analysisIn real-world data, ketamine produced rapid, meaningful relief where other treatments had not.
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review and meta-analysis
Journal of Psychopharmacology
2024
Clinical studyIn a real-world setting, IV ketamine brought rapid, lasting relief from PTSD symptoms unresponsive to other care.
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm
Journal of Pain Research
2022
Systematic reviewA review of the evidence for combining ketamine with therapy to deepen and extend results.
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Journal of Psychoactive Drugs
2019
Clinical outcomesData from three large practices showed meaningful improvement when ketamine was paired with psychotherapy.
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices
Pain Physician
2023
Randomized controlled trialIn a double-blind trial of 120 surgical patients, a single low dose of S-ketamine lowered both anxiety and pain scores across the first three days of recovery.
Sub-Anesthesia Dose of S-Ketamine Reduces Postoperative Pain and Anxiety in Patients Receiving Breast and Thyroid Surgery: A Randomized, Controlled Trial
Investigational research
The studies below discuss investigational therapies and are provided for educational purposes only. Their inclusion does not mean Mystic Health offers or recommends these therapies, or that they are FDA approved for the conditions studied.
New England Journal of Medicine
2022
Randomized trialIn a controlled trial, a single dose of psilocybin significantly eased depression in people who had not improved with other treatments.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
JAMA Psychiatry
2022
Randomized trialPairing psilocybin with therapy sharply reduced the number of heavy-drinking days for adults working to cut back.
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Nature Medicine
2023
Phase 3 trialA phase 3 trial found MDMA-assisted therapy meaningfully reduced PTSD symptoms compared with placebo.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
This is a selection of the literature, not medical advice. Whether a given treatment is right for you is determined through a medical intake with our physicians.
Spravato® is a registered trademark of Janssen Pharmaceuticals, Inc.
Visit & start
Meet us in Santa Monica. Clinic tours are free, with no obligation.
Iris
Mystic Health clinical intelligence